Get started
Author

Charles E. Mowbray

Observed names: C. E. MOWBRAY, C. E. Mowbray, C.E. Mowbray, Charles Mowbray, Charles E. Mowbray, Charles E. Mowbray, Mowbray, C.E., Mowbray, Charles, Mowbray, Charles E, Mowbray, Charles E.
Observed institutions: Drugs for Neglected Diseases Initiative, University of Nottingham, Pfizer (United Kingdom), University of Exeter, University Hospital of Geneva, Drugs for Neglected Diseases Initiative India, Loxo Oncology at Lilly (United States), Newcastle University
ORCID: 0000-0003-3538-8116
Observed ORCID: 0000-0003-3538-8116
OpenAlex ID: A5091389261
Hit and lead criteria in drug discovery for infectious diseases of the developing world
2015 · Kei Katsuno, Jeremy N. Burrows, et al. · Nature Reviews Drug Discovery · 634
Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors
2023 · Melissa L. Boby, Daren Fearon, et al. · Science · 252
Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives
2018 · Fabiana Alves, Graeme Bilbe, et al. · Clinical Microbiology Reviews · 220
The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern
2022 · Rana Abdelnabi, Caroline S. Foo, et al. · Nature Communications · 123
PDF
Concise Synthesis of Enantiomerically Pure Phenylalanine, Homophenylalanine, and Bishomophenylalanine Derivatives Using Organozinc Chemistry: NMR Studies of Amino Acid-Derived Organozinc Reagents
1998 · Richard F. W. Jackson, Rebecca J. Moore, et al. · The Journal of Organic Chemistry · 110
Drug Discovery for Kinetoplastid Diseases: Future Directions
2018 · Srinivasa P. S. Rao, Michael P. Barrett, et al. · ACS Infectious Diseases · 108
Pyrazole NNRTIs 4: Selection of UK-453,061 (lersivirine) as a Development Candidate
2009 · Charles E. Mowbray, Catherine Burt, et al. · Bioorganic & Medicinal Chemistry Letters · 105
Treatment options for second-stage gambiense human African trypanosomiasis
2014 · Gilles Eperon, Manica Balasegaram, et al. · Expert Review of Anti-infective Therapy · 104
PDF
Facing the escalating burden of dengue: Challenges and perspectives
2023 · Gathsaurie Neelika Malavige, Peter Sjö, et al. · PLOS Global Public Health · 91
PDF
Structure−Activity Relationships of 1,4-Dihydro-(1H,4H)-quinoxaline-2,3-diones as N-Methyl- d -aspartate (Glycine Site) Receptor Antagonists. 1. Heterocyclic Substituted 5-Alkyl Derivatives
2001 · M. Jonathan Fray, David J. Bull, et al. · Journal of Medicinal Chemistry · 88
DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis
2021 · Charles E. Mowbray, Stéphanie Braillard, et al. · Journal of Medicinal Chemistry · 78
Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis
2019 · Diana Caridha, Brian Vesely, et al. · International Journal for Parasitology Drugs and Drug Resistance · 78
Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis
2019 · Katrien Van Bocxlaer, Diana Caridha, et al. · International Journal for Parasitology Drugs and Drug Resistance · 76
PDF
Novel Amino-pyrazole Ureas with Potent In Vitro and In Vivo Antileishmanial Activity
2015 · Charles E. Mowbray, Stéphanie Braillard, et al. · Journal of Medicinal Chemistry · 70
Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1
2010 · Romuald Corbau, Julie Mori, et al. · Antimicrobial Agents and Chemotherapy · 62
In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series
2018 · M. Van den Kerkhof, D. Mabille, et al. · International Journal for Parasitology Drugs and Drug Resistance · 58
Novel Indazole Non-Nucleoside Reverse Transcriptase Inhibitors Using Molecular Hybridization Based on Crystallographic Overlays
2009 · Lyn H. Jones, Gill Allan, et al. · Journal of Medicinal Chemistry · 56
The role of modern drug discovery in the fight against neglected and tropical diseases
2014 · Jeremy N. Burrows, Richard L. Elliott, et al. · MedChemComm · 51
Polycycle construction via cascade radical fragmentation transannulation-cyclisation processes
1993 · Charles E. Mowbray, Gerald Pattenden · Tetrahedron Letters · 49
The Pandemic Response Box─Accelerating Drug Discovery Efforts after Disease Outbreaks
2022 · Kirandeep Samby, Dominique Besson, et al. · ACS Infectious Diseases · 44
Pharmacokinetics and Pharmacodynamics of the Nitroimidazole DNDI-0690 in Mouse Models of Cutaneous Leishmaniasis
2019 · Gert-Jan Wijnant, Simon L. Croft, et al. · Antimicrobial Agents and Chemotherapy · 44
Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: A novel histamine H4 receptor antagonist
2011 · Charles E. Mowbray, Andrew S. Bell, et al. · Bioorganic & Medicinal Chemistry Letters · 38
Pyrazole NNRTIs 1: Design and initial optimisation of a novel template
2009 · Charles E. Mowbray, Catherine Burt, et al. · Bioorganic & Medicinal Chemistry Letters · 37
Collaborative virtual screening to elaborate an imidazo[1,2- a ]pyridine hit series for visceral leishmaniasis
2021 · Yuichiro Akao, Stacie Canan, et al. · RSC Medicinal Chemistry · 32
PDF
Pyrazole NNRTIs 3: Optimisation of physicochemical properties
2009 · Charles E. Mowbray, Romuald Corbau, et al. · Bioorganic & Medicinal Chemistry Letters · 31
Works count: 85
Citation count: 3,101
H-index: 27
I10-index: 45
Year
Topic
Type